R&D News | pharmaphorum

News

Amgen's Five Prime takeover delivers gastric cancer win

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.

News

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.

News

Moderna shines spotlight on new flu vaccine data

Moderna may be facing regulatory uncertainty in the US for its vaccine pipeline, but at least its clinical data is hitting the right notes.

News

INmune Bio slumps on midstage fail for Alzheimer's drug

INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.

News

A hand holding a blackboard with the chalk-written word POSSIBLE

Novo Nordisk Foundation gives $75m for R&D 'challenges'

The Novo Nordisk Foundation's latest round of R&D funding will go towards projects in biomanufacturing, cardiometabolic diseases, and AI.

News

Controversial project aims to make artificial human genomes

A landmark project funded by Wellcome aims to develop the tools needed to synthesise human genomes – and simultaneously probe the social implications.

Amgen's Five Prime takeover delivers gastric cancer win

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

Moderna shines spotlight on new flu vaccine data

INmune Bio slumps on midstage fail for Alzheimer's drug

Novo Nordisk Foundation gives $75m for R&D 'challenges'

Controversial project aims to make artificial human genomes

Dren Bio pockets $350m for rare blood cancer programme

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks